Data Insights

AUTO-6NG by Autolus Therapeutics for Glioma: Likelihood of Approval

AUTO-6NG is under clinical development by Autolus Therapeutics and currently in Phase I for Glioma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-6NG in Glioma

Data Insights

AUTO-1/22 by Autolus Therapeutics for Hairy Cell Leukemia: Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Hairy Cell Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Hairy Cell Leukemia

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Burkitt Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase I for Burkitt Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Burkitt Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase I for Systemic Lupus Erythematosus. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Systemic Lupus Erythematosus

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

AUTO-3 by Autolus Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

AUTO-3 is under clinical development by Autolus Therapeutics and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-3 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Follicular Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Follicular Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Mantle Cell Lymphoma

Data Insights

Obecabtagene autoleucel by Autolus Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Obecabtagene autoleucel is under clinical development by Autolus Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Obecabtagene Autoleucel in Diffuse Large B-Cell Lymphoma

Data Insights

AUTO-8 by Autolus Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval

AUTO-8 is under clinical development by Autolus Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-8 in Refractory Multiple Myeloma

Data Insights

AUTO-8 by Autolus Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval

AUTO-8 is under clinical development by Autolus Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-8 in Relapsed Multiple Myeloma

Data Insights

AUTO-1/22 by Autolus Therapeutics for Burkitt Lymphoma: Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Burkitt Lymphoma

Data Insights

AUTO-1/22 by Autolus Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

AUTO-1/22 by Autolus Therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Data Insights

AUTO-1/22 by Autolus Therapeutics for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Chronic Lymphocytic Leukemia (CLL)

Data Insights

AUTO-1/22 by Autolus Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

AUTO-1/22 by Autolus Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

AUTO-3 by Autolus Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

AUTO-3 is under clinical development by Autolus Therapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...

Data Insights

AUTO-3 by Autolus Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

AUTO-3 is under clinical development by Autolus Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...